Antimalarial drug resistance, in particular resistance to Plasmodium falciparum, challenges
the treatment and control of malaria. In this Review, we summarise evolving patterns of …

Over the past 10 years, knowledge of the burden, economic costs, and consequences of
malaria in pregnancy has improved, and the prevalence of malaria caused by Plasmodium …

Background Subcutaneous administration of the monoclonal antibody L9LS protected adults
against controlled Plasmodium falciparum infection in a phase 1 trial. Whether a monoclonal …

Background The burden of malaria infection in sub-Saharan Africa among school-aged
children aged 5–15 years is underappreciated and represents an important source of …

Background Intermittent preventive treatment in pregnancy (IPTp) with dihydroartemisinin–
piperaquine is more effective than IPTp with sulfadoxine–pyrimethamine at reducing malaria …

Artemisinin-based combination therapies (ACTs) have become the mainstay for malaria
treatment in almost all malaria endemic settings. Artemisinin derivatives are highly potent …

Maternal mortality is defined by the World Health Organization (WHO) as a death that occurs
during pregnancy or within 42 days of delivery or termination of the pregnancy, from any …

Summary Background Resistance of Plasmodium falciparum to sulfadoxine-pyrimethamine
threatens the antimalarial effectiveness of intermittent preventive treatment during …

Intensified treatment and control efforts since the early 2000s have dramatically reduced the
burden of Plasmodium falciparum malaria. However, drug resistance threatens to derail this …

One hundred twenty-five million pregnant women are at risk for contracting malaria, a
preventable cause of maternal and infant morbidity and death. Malaria parasites contribute …